Series D financing round of 13 MUSD was completed in Sept 2017 and led by Forrestal Capital
Series C financing round of 10 MUSD was completed in May 2016 and led by Integer Inc. (NYSE: INT)
Series B financing round of 8 MUSD was completed in September 2014.
Series A financing round of 14 MUSD was completed in April 2012.
Main investors are:
BiomedInvest II, managed by BioMedPartners in Basel, Switzerland (www.biomedvc.com)
BB Biotech Ventures III, managed by BB Biotech in Kuesnacht, Switzerland (www.bbbiotechventures.com)
Initiative Capital Romandie, managed by Defi Gestion in Lausanne, Switzerland (www.defigestion.com)
BV5 FPCI, managed by Kreaxi in Paris, France (http://www.kreaxi.com/en/)
Integer Inc. (NYSE: INT) (www.integer.net)